Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.65), $0.09 better than the analyst estimate of ($0.74).

As of March 31, 2016, cash and cash equivalents and available-for-sale investment securities totaled $282.7 million compared with $292.6 million at December 31, 2015.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.